Response to Comment on Goldfine et al. Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD). Diabetes Care 2013;36:4132–4139 | Zendy

Allison B. Goldfine | Zendy; Kathleen A. Jablonski | Zendy; Steven E. Shoelson | Zendy; Mark A. Creager | Zendy

Open Access

Response to Comment on Goldfine et al. Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD). Diabetes Care 2013;36:4132–4139

Author(s) -

Allison B. Goldfine,

Kathleen A. Jablonski,

Steven E. Shoelson,

Mark A. Creager

Publication year - 2014

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc14-0222

Subject(s) - medicine , type 2 diabetes , diabetes mellitus , inflammation , endothelium , endothelial dysfunction , placebo , adverse effect , endocrinology , pathology , alternative medicine

In our study to target inflammation using salsalate in patients with type 2 diabetes, we demonstrate improvement in glycemia but no change in either flow-mediated, endothelium-dependent (FMD) or nitroglycerin-mediated, endothelium-independent dilation over 6 months in salsalate (3.5 g/day) compared with placebo-treated patients (1). It is important to note that no adverse cardiovascular safety signal for endothelial function was demonstrated. Our findings differ from Pierce and colleagues (2,3), who demonstrated improvement in vascular function and …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research